{"entity":{"id":"nct07477418","kind":"trial","name":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)","aka":["PRISM-TAMP"],"tldr":"A phase 1/2 trial in pancreatic cancer, run by University of Vermont, not yet recruiting.","summary":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) is a phase 1/2, interventional study registered as NCT07477418 by University of Vermont, with a registry enrolment figure of 10 participants, started 2026-12 and due to reach its primary completion in 2030-12. Interventions recorded: Gemcitabine Delivered by Transarterial Microperfusion. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC); Borderline Resectable Pancreatic Cancer; Pancreatic Neoplasms. Primary outcome: Safety and Tolerability of Neoadjuvant Transarterial Gemcitabine Delivery. Pancreatic eligibility wording from the registry: \"* Histologically confirmed pancreatic ductal adenocarcinoma (PDAC)\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07477418","url":"https://clinicaltrials.gov/study/NCT07477418"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07477418","phase":"1/2","setting":"PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP): A Phase Ib/II Open-Label Trial","sponsor":"University of Vermont","participation":[{"nct":"NCT07477418","source":"https://clinicaltrials.gov/study/NCT07477418","fetchedAt":"2026-10-07T16:55:46.774Z","studySha256":"31e7b227a6bce13782e329e61c1f5c214a991e671ce07132f9e8e8ba8454ef23","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-03-17","leadSponsor":"University of Vermont","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":10,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2026-12","startedType":"estimated","enrolled":10,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07477418/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}